Bruce A. Hay
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bruce A. Hay.
Journal of Pharmacology and Experimental Therapeutics | 2008
Julie Hawkins; Michael D. Robbins; Laurie C. Warren; Donghui Xia; Stephen F. Petras; James J. Valentine; Alison H. Varghese; Ing-Kae Wang; Timothy A. Subashi; Lorraine D. Shelly; Bruce A. Hay; Katherine T. Landschulz; Kieran F. Geoghegan; H. James Harwood
Sterol regulatory element-binding proteins (SREBPs) are major transcriptional regulators of cholesterol, fatty acid, and glucose metabolism. Genetic disruption of SREBP activity reduces plasma and liver levels of cholesterol and triglycerides and insulin-stimulated lipogenesis, suggesting that SREBP is a viable target for pharmacological intervention. The proprotein convertase SREBP site 1 protease (S1P) is an important posttranscriptional regulator of SREBP activation. This report demonstrates that 10 μM PF-429242 (Bioorg Med Chem Lett 17:4411–4414, 2007), a recently described reversible, competitive aminopyrrolidineamide inhibitor of S1P, inhibits endogenous SREBP processing in Chinese hamster ovary cells. The same compound also down-regulates the signal from an SRE-luciferase reporter gene in human embryonic kidney 293 cells and the expression of endogenous SREBP target genes in cultured HepG2 cells. In HepG2 cells, PF-429242 inhibited cholesterol synthesis, with an IC50 of 0.5 μM. In mice treated with PF-429242 for 24 h, the expression of hepatic SREBP target genes was suppressed, and the hepatic rates of cholesterol and fatty acid synthesis were reduced. Taken together, these data establish that small-molecule S1P inhibitors are capable of reducing cholesterol and fatty acid synthesis in vivo and, therefore, represent a potential new class of therapeutic agents for dyslipidemia and for a variety of cardiometabolic risk factors associated with diabetes, obesity, and the metabolic syndrome.
Bioorganic & Medicinal Chemistry Letters | 2001
Bruce A. Hay; Bridget Mccarthy Cole; Frank M. DiCapua; Glen W. Kirk; Marianne C. Murray; Rona A. Nardone; Dennis J. Pelletier; Anthony Paul Ricketts; Alan Robertson; Todd W. Siegel
The first potent small molecule sst2 antagonists are reported. Altering known sst2 agonist molecules yielded compounds with high sst2 binding affinity and full antagonist activity. Compound 7a, for example, displaced somatostatin binding to the sst2 receptor with an IC(50)=2.9 nM and antagonized somatostatin action with an IC(50)=29nM.
Tetrahedron Letters | 1994
Richard S. Glass; Waheguru Pal Singh; Bruce A. Hay
Abstract Oxidation of substituted thietanes 1a, b, and 6 with m-chloroperoxybenzoic acid preferentially gives the corresponding cis-sulfoxides with modest diastereoselectivity. Selective oxidation of the trans over the cis diastereomeric pairs of sulfoxides 2a, 3a; 2b, 3b; 7, 8 occurs with moderate selectivity with m-chloroperoxybenzoic acid. The basis for these selectivities is hydrogen bonding between the 3-substituent and the peracid.
Archive | 1990
Bruce A. Hay
Bioorganic & Medicinal Chemistry Letters | 2007
Bruce A. Hay; Barbara Abrams; Allice Y. Zumbrunn; James J. Valentine; Laurie C. Warren; Stephen F. Petras; Lorraine D. Shelly; Angela Xia; Alison H. Varghese; Julie Hawkins; Jennifer A. Van Camp; Michael D. Robbins; Katherine T. Landschulz; H. James Harwood
Archive | 2001
Bruce A. Hay; Bridget Mccarthy Cole; Anthony Paul Ricketts
Archive | 2007
Bruce Allen Lefker; Michael Aaron Brodney; Subas M. Sakya; Bruce A. Hay; Matthew D. Wessel; Edward L. Conn
Journal of Agricultural and Food Chemistry | 1991
Bruce A. Hay; John W. Homiski
Archive | 1990
Bruce A. Hay
Archive | 2001
Bridget Mccarthy Cole; Anthony Paul Ricketts; Bruce A. Hay